Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters.
about
The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonistSelective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5DCG-IV selectively attenuates rapidly triggered NMDA-induced neurotoxicity in cortical neuronsPrevention and treatment of brain ischaemia.Beta-N-oxalylamino-L-alanine action on glutamate receptorsThe changing landscape of ischaemic brain injury mechanisms.Two classes of N-methyl-D-aspartate recognition sites: differential distribution and differential regulation by glycine.Central non-opioid physiological and pathophysiological effects of dynorphin A and related peptides.Effect of noncompetitive blockade of N-methyl-D-aspartate receptors on the neurochemical sequelae of experimental brain injury.CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activityClinical and EEG response to anticonvulsants in neonatal seizuresHuman peripheral monocytes express putative receptors for neuroexcitatory amino acids.Quantitative autoradiography of [3H]-MK-801 binding sites in mammalian brainAntagonism of N-methylaspartate and synaptic responses of neurones in the rat ventrobasal thalamus by ketamine and MK-801.A quantitative study of the actions of excitatory amino acids and antagonists in rat hippocampal slices.Convulsions induced by centrally administered NMDA in mice: effects of NMDA antagonists, benzodiazepines, minor tranquilizers and anticonvulsants.Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cellsReversible loss of dendritic spines and altered excitability after chronic epilepsy in hippocampal slice cultures.Paeoniflorin inhibits excitatory amino acid agonist-and high-dose morphine-induced nociceptive behavior in mice via modulation of N-methyl-D-aspartate receptors.Ketamine : from medicine to misuse.Nitric oxide: foe or friend to the injured brain?Effect of sustained pyridoxine treatment on seizure susceptibility and regional brain amino acid levels in genetically epilepsy-prone BALB/c mice.Identification and properties of N-methyl-D-aspartate receptors in rat brain synaptic plasma membranes.Ultrastructural description of glutamate-, aspartate-, taurine-, and glycine-like immunoreactive terminals from five rat brain regions.Glutamate in the mammalian CNS.Structural, conformational, and stereochemical requirements of central excitatory amino acid receptors.Brain protection: physiological and pharmacological considerations. Part I: The physiology of brain injury.Hypoxic-ischemic damage of the basal ganglia. Case reports and a review of the literature.Historical overview. Calcium, ischemia, and death of brain cells.N-methyl-D-aspartate antagonists: ready for clinical trial in brain ischemia?Digital processing of the current noise evoked by kainate in cerebellar granule cells.Cognition activators.Neurotoxicity at the N-methyl-D-aspartate receptor in energy-compromised neurons. An hypothesis for cell death in aging and disease.Selective vulnerability of brain: new insights from the excitatory synapse.Haloperidol prevents induction of the hsp70 heat shock gene in neurons injured by phencyclidine (PCP), MK801, and ketamine.Effect of impact trauma on neurotransmitter and nonneurotransmitter amino acids in rat spinal cord.A potential role for excitotoxins in the pathophysiology of spinal cord injury.CNS stimulation and PGE2 release. III. Pentamethylenetetrazole-induced seizures.NMDA prevents alcohol-induced neuronal cell death of cerebellar granule cells in culture.The neurotrophic factor, n-hexacosanol, reduces the neuronal damage induced by the neurotoxin, kainic acid.
P2860
Q24629716-86F72063-488E-4817-906A-F5AAD97C1433Q28282369-8E8E3665-5D03-427E-B9EB-776A0311D232Q28285070-6FA57AD2-F52A-41D0-943C-C327154279A3Q28307318-1CB79BD9-D8FF-4A7E-BD93-628B6F8DBD4FQ28342817-AC8DFCD3-4533-4CC9-ABB8-3E15C8936FE1Q33678157-B7868CA6-D1DC-430B-8A01-832A005C31EAQ33689000-8A3130FF-80D6-4D1D-AA7A-BE563626070EQ33921068-E9D437ED-8B0E-4009-B242-D66E680134DFQ33937321-CC470B79-6E4E-4E31-ADF3-7133E81C0635Q35001085-8B002CBA-44BF-4FCA-ADAF-FB6197AB6492Q35069171-4EA1B50D-5BCB-436F-9CE2-7BE7DF558554Q35605237-A5E86FE3-B1E4-4B6D-B75D-C6CEE1A65188Q35755389-0D8676F1-FAED-40BC-B2A6-CF1143101451Q35755565-736C784F-24C6-41B2-B83F-A224602911A2Q35755873-BF8EC643-D182-4D02-905C-09033ED58FF0Q35756859-1CA3137E-03B7-4663-8D6B-944E7C8F4334Q35884655-CBA1FEDC-6110-4577-982E-5037DB4C96E3Q36041067-C3AEB2D6-68F4-4B79-BB97-2BF4CE452B30Q36085494-2F27D8A8-892B-4116-8CBD-D2172FA0BC38Q36418016-53804B7C-1BC0-41B4-9419-072DE5019E21Q36610714-E2441BA8-B162-41BE-A1E9-A08F765689A4Q36775186-86621756-8F2F-4B54-8E80-20B9CEFDC3CBQ37402220-CAFA13D7-599B-42E6-91A2-F4461F0B25E5Q37587644-33CF208B-0AFA-4F0E-B42C-02AEFF8651F2Q37610496-73AF588D-F426-4EBE-939C-BA64282F2B0FQ37870673-4B63880B-14A3-499E-BA82-1B1E9E776D8BQ37956410-9428B4EB-7050-4BBD-A9ED-0232227DB983Q38124126-BE82BCA6-F57B-44E0-93A7-D383EE38E132Q38188975-2D1921F2-04A7-4393-BC33-E38885C013E9Q38346075-4C306798-7297-4B12-B500-5FB9A1DBB7E6Q39445100-B226A28F-E948-4549-8CE1-7E4D16EFC517Q39515095-7A704FBE-04C8-4EB0-A690-70B1FC5D9F86Q39528853-2CEE60C8-3CE8-480A-9C06-EE3DEC1FC3E8Q39706134-B6574E94-DA68-4009-BEB8-E9448503751BQ41101154-643F16D8-7C30-4E1A-87D3-63EAA654CDF6Q41276011-68E2E92E-65D4-49A7-AB38-D443CC8A4D7FQ41336337-53F37A4C-1560-45BA-955D-E20655F114EBQ41350425-B5A24762-329A-474D-88C7-392D4E461646Q41653165-AABF2B4D-FEF2-4582-9AFC-A4AB4054E022Q41906370-D813F74D-629D-4B4D-B641-107F5755BA4A
P2860
Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
Possible therapeutic applicati ...... amino acid neurotransmitters.
@en
Possible therapeutic applicati ...... amino acid neurotransmitters.
@nl
type
label
Possible therapeutic applicati ...... amino acid neurotransmitters.
@en
Possible therapeutic applicati ...... amino acid neurotransmitters.
@nl
prefLabel
Possible therapeutic applicati ...... amino acid neurotransmitters.
@en
Possible therapeutic applicati ...... amino acid neurotransmitters.
@nl
P356
P1433
P1476
Possible therapeutic applicati ...... amino acid neurotransmitters.
@en
P2093
P304
P356
10.1042/CS0680113
P407
P577
1985-02-01T00:00:00Z